Key Takeaways
- Victoza is liraglutide, a daily GLP-1 injection. Ozempic is semaglutide, a once-weekly GLP-1 injection. Both are FDA-approved for type 2 diabetes.
- Ozempic produces more A1C reduction and more weight loss than Victoza in head-to-head trials (SUSTAIN 10, Capehorn et al., Diabetes Metab 2020).
- Victoza requires 365 injections a year. Ozempic requires 52. That single fact drives most patient preference.
- Cash list price runs about $815 per Ozempic pen and roughly $940 per Victoza box (3 pens), per April 2026 manufacturer data.
- Side-effect profiles are similar (nausea, GI upset). Ozempic's weekly cadence tends to produce smoother symptom curves than Victoza's daily peaks.
Direct answer (40-60 words)
Victoza (liraglutide) is a daily GLP-1 injection approved in 2010. Ozempic (semaglutide) is a once-weekly GLP-1 injection approved in 2017. Both treat type 2 diabetes. In head-to-head trials, Ozempic produced larger A1C drops and more weight loss than Victoza, with similar side effects and a far simpler injection schedule.
Comparing providers? Read our full Saxenda vs Zepbound vs Wegovy comparison.
Table of contents
- The 30-second answer
- What each drug actually is
- How dosing compares
- A1C and blood-sugar results, head to head
- Weight loss: how the two stack up
- Side effects and tolerability
- Heart and kidney outcomes data
- Cost, insurance, and coupons in 2026
- Switching from Victoza to Ozempic
- Who should pick which
- FAQ
- Sources
- Footer disclaimers
What each drug actually is
Victoza and Ozempic both belong to the glucagon-like peptide-1 (GLP-1) receptor agonist class. They mimic an incretin hormone the gut releases after meals. The hormone tells the pancreas to release insulin, tells the liver to release less glucose, slows stomach emptying, and dampens appetite signaling in the brain.
Not sure which GLP-1 is right for you?
Take a 2-minute assessment and get a personalized recommendation after licensed provider review.
Take the Assessment →The difference is the molecule.
Victoza contains liraglutide. Liraglutide is a GLP-1 analog with a fatty-acid chain that binds to albumin in the blood, which extends the half-life from minutes (native GLP-1) to about 13 hours. That half-life is long enough for once-daily injection but not weekly.
Ozempic contains semaglutide. Semaglutide also has a fatty-acid linker but with structural changes (an aminobutyric acid spacer, a different fatty-diacid chain) that extend half-life to about 165 hours, which is roughly a week. That's why semaglutide can be dosed once weekly while liraglutide can't.
Both drugs are made by Novo Nordisk. Victoza got FDA approval in January 2010. Ozempic followed in December 2017. A higher-dose semaglutide (Wegovy 2.4 mg) is approved for chronic weight management; Wegovy is technically the same molecule as Ozempic, just at a higher max dose.
How dosing compares
| Feature | Victoza (liraglutide) | Ozempic (semaglutide) |
|---|---|---|
| Schedule | Once daily | Once weekly |
| Starting dose | 0.6 mg/day x 1 week | 0.25 mg/week x 4 weeks |
| Maintenance dose | 1.2 mg/day (max 1.8 mg) | 0.5 mg, 1 mg, or 2 mg/week |
| Pen format | Multi-dose 3 mL pen, 18 mg | Multi-dose 1.5 mL or 3 mL pen |
| Doses per box | Variable per pen (3 pens/box) | 4 doses per pen, 4 pens/box typical |
| Storage before first use | Refrigerate | Refrigerate |
| Storage after first use | 30 days room temp | 56 days room temp |
The titration schedules look similar on paper but feel different in practice. Victoza's titration is one week long: 0.6 mg daily for week 1, then 1.2 mg from week 2 forward. If 1.2 mg isn't enough A1C control, providers can move to 1.8 mg.
Ozempic uses a four-week step at each dose: 0.25 mg for weeks 1 to 4, 0.5 mg for weeks 5 to 8, and so on. Many patients tolerate higher steady-state doses on Ozempic because the weekly cadence avoids the daily nausea peaks that can come with liraglutide.
A patient on Victoza injects 365 times a year. A patient on Ozempic injects 52 times. For people who hate needles, that gap matters.
A1C and blood-sugar results, head to head
The cleanest comparison is SUSTAIN 10 (Capehorn et al., Diabetes Metab 2020), a 30-week randomized trial of 577 adults with type 2 diabetes inadequately controlled on metformin. Half got semaglutide 1 mg weekly, half got liraglutide 1.2 mg daily.
Results at week 30:
- A1C reduction: semaglutide 1.7%, liraglutide 1.0% (difference 0.69%, p < 0.0001)
- A1C below 7%: semaglutide 80%, liraglutide 46%
- Weight loss: semaglutide 5.8 kg, liraglutide 1.9 kg (difference 3.8 kg, p < 0.0001)
A larger meta-analysis pooling SUSTAIN trials versus liraglutide trials (Pratley et al., Lancet Diabetes Endocrinol 2018) showed roughly the same pattern: semaglutide 1 mg outperformed liraglutide 1.8 mg on A1C by about 0.3 to 0.5 percentage points, and on weight by 2 to 4 kg.
The clinical takeaway: at typical maintenance doses, Ozempic produces meaningfully better blood-sugar and weight outcomes than Victoza. The semaglutide molecule is simply more potent at the GLP-1 receptor, and weekly dosing allows more sustained drug exposure.
Weight loss: how the two stack up
Neither Victoza nor Ozempic is FDA-approved for weight loss specifically. (Saxenda, which is liraglutide 3 mg, is the weight-loss version of Victoza. Wegovy, which is semaglutide 2.4 mg, is the weight-loss version of Ozempic.) But both Victoza and Ozempic produce weight loss as a side effect of treating diabetes, and patients shopping for "the better drug" usually care about that.
Average weight loss in published trials:
| Drug | Dose | Trial | Average weight loss at 6 months |
|---|---|---|---|
| Victoza | 1.8 mg/day | LEAD-2 | 2.8 kg (about 6 lbs) |
| Victoza | 1.8 mg/day | SUSTAIN 10 | 1.9 kg at 30 weeks (about 4 lbs) |
| Ozempic | 0.5 mg/week | SUSTAIN 7 | 4.6 kg (about 10 lbs) |
| Ozempic | 1 mg/week | SUSTAIN 7 | 6.5 kg (about 14 lbs) |
| Ozempic | 1 mg/week | SUSTAIN 10 | 5.8 kg at 30 weeks (about 13 lbs) |
Real-world data tends to show smaller numbers than trial data because adherence is lower outside of trials. A retrospective claims-data analysis (Brown et al., Diabetes Obes Metab 2022) found average 6-month weight loss of roughly 2.5 to 3.5 kg on Ozempic 1 mg in clinical practice.
Patients seeking dedicated weight-loss treatment (BMI 30+, or 27+ with comorbidity) usually do better on Wegovy or Zepbound, which are dosed higher and trial-tested for obesity specifically.
Side effects and tolerability
Both medications share the GLP-1 class side-effect profile:
- Nausea (most common, especially during titration)
- Vomiting
- Diarrhea or constipation
- Decreased appetite
- Stomach pain
- Headache
- Injection-site reactions
In SUSTAIN 10, GI side effects were reported by 43% of semaglutide patients and 38% of liraglutide patients. Discontinuation rates due to side effects were 11% on semaglutide vs 7% on liraglutide.
The catch is that nausea on Victoza arrives daily because the dose arrives daily. Many patients describe a 2 to 4 hour window of mild nausea after each injection. Ozempic concentrates that into the 24 to 48 hours after injection day, then fades.
Serious risks shared by both drugs:
- Pancreatitis. Rare but real. Severe upper abdominal pain that radiates to the back warrants emergency evaluation. FAERS data suggests roughly 1 to 3 cases per 1,000 patient-years on either drug.
- Gallbladder disease. Both drugs raise gallstone risk during rapid weight loss. The risk is dose-related and worse with faster weight loss.
- Thyroid C-cell tumors (boxed warning). Based on rodent studies; no proven human signal. Both drugs are contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.
- Acute kidney injury. Usually from severe dehydration via vomiting or diarrhea, not direct kidney toxicity.
The boxed warning and contraindication list is identical for both drugs.
Heart and kidney outcomes data
This is where the comparison gets more nuanced.
LEADER trial (Marso et al., NEJM 2016) tested Victoza in 9,340 adults with type 2 diabetes and high cardiovascular risk. Over 3.8 years, Victoza reduced major adverse cardiovascular events (MACE) by 13% versus placebo, including a 22% reduction in cardiovascular death. Victoza got an FDA label update in 2017 for reducing cardiovascular risk in adults with T2D and established cardiovascular disease.
SUSTAIN 6 (Marso et al., NEJM 2016) tested Ozempic in 3,297 adults with T2D and high CV risk. Over 2.1 years, Ozempic reduced MACE by 26% versus placebo. The benefit was driven mostly by stroke and non-fatal MI reduction. Ozempic got a similar FDA label update in 2020.
FLOW trial (Perkovic et al., NEJM 2024) showed semaglutide reduced kidney disease progression by 24% in adults with T2D and chronic kidney disease.
Both drugs have proven cardiovascular benefit. Ozempic also has documented kidney-protection benefit at this point. Victoza's CV evidence is older and on a larger trial; Ozempic's is broader, including kidney outcomes.
For patients with established cardiovascular disease where the question is "which one has CV outcome data," both qualify. For patients with diabetic kidney disease, Ozempic has more recent supporting evidence.
Cost, insurance, and coupons in 2026
Per April 2026 published manufacturer pricing:
| Drug | Cash list price (per month) | Manufacturer savings card |
|---|---|---|
| Victoza | About $940 (one box, 3 pens) | Yes, $25/fill if commercial insurance |
| Ozempic | About $815 (one pen, 4-week supply) | Yes, $25/fill if commercial insurance |
Insurance coverage:
- Most commercial plans cover at least one of the two for type 2 diabetes, often with prior authorization. Tier placement varies; many plans now place semaglutide on tier 2 or 3.
- Medicare Part D has covered both for diabetes (Medicare doesn't cover GLP-1s for weight loss alone). Coverage and copays vary by plan.
- Medicaid coverage varies state by state for either drug.
If a plan covers one but not the other, the savings-card price doesn't apply for cash patients. Cash patients with no insurance pay close to list. Both manufacturer savings cards exclude Medicare, Medicaid, and Tricare patients per Inflation Reduction Act and stacking rules.
For patients who can't afford brand-name liraglutide or semaglutide, options include:
- Generic liraglutide (approved by FDA December 2024). Available from a few generic manufacturers at lower cost than Victoza brand.
- Compounded semaglutide. Available through state-licensed compounding pharmacies in response to an individual prescription. Compounded semaglutide is not FDA-approved and is not interchangeable with Ozempic. Pricing varies by provider.
- Compounded tirzepatide. A different molecule (dual GLP-1/GIP) that produces larger weight loss in trials. Also not FDA-approved.
Switching from Victoza to Ozempic
A common scenario: a patient on Victoza for 6 to 18 months wants weekly dosing or better A1C/weight results. Provider-supervised switches typically follow this protocol:
- Take the last Victoza dose on day 0.
- Skip 24 hours. No GLP-1 dose on day 1.
- Start Ozempic 0.25 mg on day 2. This is the standard starting dose, regardless of how long the patient was on Victoza.
- Hold at 0.25 mg for 4 weeks, then escalate to 0.5 mg, then to 1 mg or 2 mg as needed.
The reason for restarting at the lowest dose is that the weekly cadence and higher peak exposure of semaglutide can produce more nausea than daily liraglutide, even at "equivalent" doses. Skipping titration is a common cause of switch failure.
Some providers will move directly from Victoza 1.8 mg to Ozempic 0.5 mg without titrating, but this carries higher GI side-effect risk. Standard guidelines recommend the four-week 0.25 mg step.
Switching from Ozempic to Victoza (rare, but sometimes needed for affordability or coverage reasons) follows a similar pattern: stop Ozempic for 7 days, then start Victoza 0.6 mg daily for one week, then up-titrate.
Who should pick which
Victoza tends to be the better choice when:
- Insurance covers Victoza but not Ozempic
- The patient prefers daily dosing for habit reasons
- Generic liraglutide is the lowest-cost option available
- The patient is sensitive to the nausea peaks weekly cadence can produce
- Pediatric type 2 diabetes (Victoza is approved for ages 10+; Ozempic is adults only)
Ozempic tends to be the better choice when:
- The patient wants weekly dosing
- A1C is far from target and needs aggressive reduction
- Weight loss is a meaningful secondary goal
- The patient has established cardiovascular disease (both have CV indications, but Ozempic data is more recent)
- The patient has chronic kidney disease (FLOW data supports Ozempic specifically)
For most adults with type 2 diabetes choosing between these two today, Ozempic is the more potent option with simpler dosing. Victoza remains a valid choice for cost or pediatric reasons.
FAQ
Is Victoza the same as Ozempic? No. Victoza is liraglutide, a daily GLP-1 injection approved in 2010. Ozempic is semaglutide, a weekly GLP-1 injection approved in 2017. Same drug class, different molecules, different schedules, different potency.
Which is better, Victoza or Ozempic? Ozempic produces larger A1C reductions and more weight loss in head-to-head trials (SUSTAIN 10, Capehorn et al., 2020). Victoza is daily; Ozempic is weekly. For most patients, Ozempic is the more potent option, but coverage and cost can make Victoza the better choice for some.
Can I switch from Victoza to Ozempic? Yes, with provider supervision. The standard protocol: stop Victoza, wait 24 hours, then start Ozempic at the 0.25 mg starting dose for 4 weeks, then up-titrate. Skipping titration usually causes nausea and is not recommended.
Does Victoza or Ozempic cause more weight loss? Ozempic. In SUSTAIN 10, semaglutide 1 mg weekly produced 5.8 kg average weight loss over 30 weeks vs 1.9 kg for liraglutide 1.2 mg daily. Higher Ozempic doses (2 mg) and higher Victoza doses (1.8 mg) narrow the gap slightly but Ozempic stays ahead.
How long does Victoza stay in your system vs Ozempic? Liraglutide has a half-life of about 13 hours. Semaglutide's half-life is about 165 hours (roughly 7 days). Victoza clears the body in 2 to 3 days after the last dose. Ozempic takes about 5 weeks to fully clear.
Are the side effects the same on Victoza and Ozempic? The side-effect profile is the same: nausea, vomiting, diarrhea, constipation, abdominal pain. Frequency is similar. The pattern differs: Victoza causes daily mild nausea peaks; Ozempic concentrates symptoms in the 1 to 2 days after injection.
Can you take Victoza and Ozempic together? No. Both are GLP-1 receptor agonists. Combining them doesn't improve efficacy and increases side-effect risk (severe nausea, hypoglycemia in patients also on insulin or sulfonylureas). Providers do not co-prescribe these drugs.
Is generic Victoza available? Yes. The FDA approved generic liraglutide in December 2024. Several manufacturers now produce it at prices below brand Victoza. Generic semaglutide (Ozempic) is not yet available.
Which is cheaper, Victoza or Ozempic? Brand list prices are roughly comparable (both around $815 to $940 per month). With manufacturer savings cards, both can be $25 per fill for commercially insured patients. Generic liraglutide is now cheaper than brand-name Ozempic for cash patients.
Can I use Victoza for weight loss? Victoza is FDA-approved for type 2 diabetes only. Saxenda, which is liraglutide 3 mg, is the FDA-approved weight-loss version. Off-label use of Victoza for weight loss is uncommon because Saxenda exists at the appropriate dose.
Is Ozempic safer than Victoza? Both have similar safety profiles. Both carry the boxed warning for thyroid C-cell tumors. Both can cause pancreatitis and gallbladder issues. Ozempic has additional data showing kidney benefit (FLOW trial, 2024). Victoza has the longest cardiovascular outcomes track record.
Do Victoza and Ozempic both lower A1C? Yes, both meaningfully reduce A1C. Average A1C reduction is roughly 1.0 to 1.4 percentage points on Victoza 1.8 mg and 1.5 to 1.8 percentage points on Ozempic 1 to 2 mg, depending on baseline.
Related guides
- Victoza vs Ozempic: Which GLP-1 Is Right for Your Weight Loss and Diabetes Goals
- Lemon Balm vs Ozempic: Why a Medicinal Herb Can't Replace a GLP-1 Medication (and What the Research Actually Shows)
- Ozempic vs Mounjaro: Different Drugs, Different Receptors, Different Trials
- What Is the Difference Between Zepbound and Ozempic? The Active Ingredient, Receptor Targets, and Clinical Outcomes That Actually Matter
- Does Mounjaro Work Better Than Ozempic? The Head-to-Head Data and What It Actually Means for You
- Ozempic vs Wegovy: what actually matters in 2026
Sources
- Capehorn MS, et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to metformin (SUSTAIN 10). Diabetes Metab. 2020;46(2):100-109.
- Pratley R, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7). Lancet Diabetes Endocrinol. 2018;6(4):275-286.
- Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016;375:311-322.
- Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN 6). N Engl J Med. 2016;375:1834-1844.
- Perkovic V, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024;391:109-121.
- Brown E, et al. Real-world effectiveness of GLP-1 receptor agonists in type 2 diabetes. Diabetes Obes Metab. 2022;24(8):1568-1577.
- FDA prescribing information, Victoza (liraglutide), revised 2024.
- FDA prescribing information, Ozempic (semaglutide), revised 2024.
- American Diabetes Association. Standards of Care in Diabetes 2025. Diabetes Care. 2025;48(Suppl 1).
- Davies M, et al. Semaglutide versus liraglutide for treatment of obesity. Diabetes Obes Metab. 2020;22(11):2125-2129.
- Buse JB, et al. Switching from sitagliptin to liraglutide. Diabetes Care. 2010;33:1300-1303.
- Nauck MA, et al. GLP-1 receptor agonists in type 2 diabetes: review. Lancet Diabetes Endocrinol. 2021;9(4):217-229.
- FDA approval letter, generic liraglutide, December 2024.
- American Diabetes Association. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2024;47(Suppl 1):S158-S178.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Victoza, Ozempic, Saxenda, and Wegovy are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →